术后并发症与2型糖尿病对乳腺癌复发和死亡率的影响
术后并发症未增加早期复发(aHR=1.04,95%CI 0.96-1.13)或晚期复发(aHR=0.90,95%CI 0.80-1.02)风险,但增加死亡风险(aHR=1.11,95%CI 1.06-1.16),合并2型糖尿病者死亡风险更高(aHR=1.50,95%CI 1.30-1.73)。
要点
- 术后并发症不增加乳腺癌早期或晚期复发风险。
- 术后并发症与全因死亡风险升高独立相关。
- 合并2型糖尿病的术后并发症患者死亡风险进一步增加。
核心结论
- 乳腺癌原发手术后的术后并发症不影响复发风险,但对生存有负面影响,尤其在合并2型糖尿病的女性中。
研究设计与样本
- 术后30天内的全身性和手术部位并发症通过诊断编码定义;早期复发(诊断后<10年)从DBCG获取,晚期复发(诊断后≥10年)通过经验证的注册算法确定。
主要发现
- 有并发症与无并发症者早期复发分别747例和5756例(IR 19.7 vs 17.9/1000人年,aHR=1.04,95%CI 0.96-1.13)。
- 有并发症与无并发症者晚期复发分别314例和3314例(IR 23.9 vs 26.0/1000人年,aHR=0.90,95%CI 0.80-1.02)。
- 有并发症者死亡率高于无并发症者(aHR=1.11,95%CI 1.06-1.16);合并2型糖尿病者较无2型糖尿病者死亡风险更高(aHR=1.50,95%CI 1.30-1.73)。
- 合并2型糖尿病未改变术后并发症与复发之间的关联。
临床怎么用
- 术后并发症不应被视为乳腺癌复发的危险因素,但需关注其对生存的影响。
- 对合并2型糖尿病的术后并发症患者应加强围术期管理和随访以改善生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Type 2 diabetes (T2D) is associated with increased risk of complications after breast cancer surgery. This study investigated systemic and surgical-site postoperative complications and the risk of early and late breast cancer recurrence and mortality, overall, and according to T2D status. METHODS: From the Danish Breast Cancer Group (DBCG) and Danish registries, a cohort of women with incident early-stage breast cancer diagnosed 1996-2017 was assembled. All women underwent mastectomy or breast-conserving surgery. Using diagnostic codes, systemic and surgical-site complications within 30 days of surgery were defined. Early recurrence (<10 years from diagnosis) was ascertained from the DBCG and late recurrence (≥10 years after diagnosis) via a validated registry-based algorithm. Incidence rates (IRs) per 1000 person-years were calculated, and Cox regression was used to estimate adjusted hazard ratios (aHRs) of early and late recurrence, and death, according to postoperative complications. Potential effect measure modification by T2D was evaluated. RESULTS: Among 58 198 women undergoing breast cancer surgery, 6285 (10.8%) had postoperative complications. Overall, 747 and 5756 women with and without complications developed early recurrence (IR: 19.7 and 17.9, aHR = 1.04, 95% c.i. 0.96, 1.13), whereas 314 and 3314 women developed late recurrence (IR: 23.9 and 26.0, and aHR = 0.90, 95% c.i. 0.80, 1.02). Prevalent T2D did not impact these findings. Women with postoperative complications had higher mortality rates than those without complications (aHR = 1.11; 95% c.i. 1.06, 1.16); especially those with T2D versus no T2D (aHR = 1.50; 95% c.i. 1.30, 1.73). CONCLUSION: Postoperative complications after breast cancer primary surgery did not impact recurrence risk but had a negative impact on survival, especially in women with T2D.
引用
- Kjærgaard KA, Christiansen P, Borgquist S, et al. Impact of postoperative complications and type 2 diabetes on breast cancer recurrence and mortality. Br J Surg. 2025. PMID: 40847759. doi:10.1093/bjs/znaf176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。